Alnylam Pharmaceuticals, Inc. (ALNY)
FDA Applications
Note: This list only includes applications that have been responded to by the FDA.
| Application | Product Name | Active Ingredient | Form | Strength | Status | ||
|---|---|---|---|---|---|---|---|
| NDA215515 - ALNYLAM PHARMS INC | |||||||
| AMVUTTRA | VUTRISIRAN SODIUM | SOLUTION;SUBCUTANEOUS | EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML) | Prescription | |||
| NDA214103 - ALNYLAM PHARMS INC | |||||||
| OXLUMO | LUMASIRAN SODIUM | SOLUTION;SUBCUTANEOUS | EQ 94.5MG BASE/0.5ML (EQ 94.5MG BASE/0.5ML) | Prescription | |||
| NDA212194 - ALNYLAM PHARMS INC | |||||||
| GIVLAARI | GIVOSIRAN SODIUM | SOLUTION;SUBCUTANEOUS | EQ 189MG BASE/ML (EQ 189MG BASE/ML) | Prescription | |||
| NDA210922 - ALNYLAM PHARMS INC | |||||||
| ONPATTRO | PATISIRAN SODIUM | SOLUTION;INTRAVENOUS | EQ 10MG BASE/5ML (EQ 2MG BASE/ML) | Prescription | |||